Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

Background: Triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy (NAC) face high risk of recurrence. BREASTIMMUNE-03 trial evaluates the efficacy of nivolumab and ipilimumab combination compared to capecitabine as adjuvant treatment. Methods: This multic...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Frédéric Viret, Christelle Levy, Aurélien Robert, Julien Grenier, Laura Mansi, Jean-Philippe Spano, Anne Patsouris, Olfa Derbel, Christelle Jouannaud, Jean Marc Ferrero, Jean Sébastien Frenel, Yann Molin, Louis Doublet, Pierre-Etienne Heudel, Jean-Yves Pierga, Gwenaële Garin, David Pérol, Thomas Bachelot
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2026-02-01
Seri Bilgileri:	Breast
Konular:	TNBC Immunotherapy Immune checkpoint inhibitors Nivolumab Ipilimumab Capecitabine
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S0960977625008653
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!